PD-1 blockade during T cell priming enhances long-term protection against metastatic tumors by epigenetically tuning T cell exhaustion

Authors:
  • TDTeresa Dinter
    Teresa Dinter
  • SMSebastian Mackowiak
    Sebastian Mackowiak
  • ZRZachary J. Rogers
    Zachary J. Rogers
  • VBVidit Bhandarkar
    Vidit Bhandarkar
  • MCMolly Y. Carney
    Molly Y. Carney
  • DMDuncan Morgan
    Duncan Morgan
  • LPLorelai Pop
    Lorelai Pop
  • FCFiona Chatterjee
    Fiona Chatterjee
  • ELEmi Lutz
    Emi Lutz
  • YJYajit Jain
    Yajit Jain
  • ARAdityanarayanan Radhakrishnan
    Adityanarayanan Radhakrishnan

Abstract
In cancer, CD8 + T cell responses are dominated by exhausted T cells, which can be reinvigorated using immune checkpoint blockade therapy and can control large tumors. However, it remains unclear which T cell fate best supports long-term immunity following tumor regression or clearance and a period of minimal antigen load. This question is particularly relevant following surgical tumor resection, when tuning the immune system could prevent recurrence. To determine which T cell fate provides durable protection following surgery and metastatic rechallenge, we modulated T cell priming using anti-PD-1, IFN-β or agonistic anti-CD40 and assessed effects on CD8 + T cell differentiation and overall survival. IFN-β and anti-CD40 promoted effector and memory-like T cell states, respectively, whereas anti-PD-1 did not markedly alter T cell differentiation, yet conferred the greatest survival benefit against metastatic tumors. Notably, anti-PD-1 induced epigenetic remodeling, which was detectable upon metastatic recall, consistent with the maintenance of a circulatory intermediate-exhausted T cell state. Thus, while effector and memory precursor-like T cells could be generated with IFN-β and agonistic anti-CD40, only the intermediate-exhausted T cell state driven by anti-PD-1 supported durable anti-tumor immunity. Summary: This study shows that PD-1 blockade during T cell priming promotes a circulatory intermediate-exhausted CD8⁺ T cell state that uniquely supports durable anti-tumor immunity after surgical resection and metastatic challenge, outperforming effector or memory-like T cell responses generated by IFN-β or CD40 agonist treatment, respectively.
Funding Information
  • National Cancer Institute (P30-CA14051)
  • Ludwig Center MIT (n/a)

This publication has 65 references indexed in Scilit: